Last year I submitted Leronlimab's name to the Rec
Post# of 157599
(Total Views: 567)
Posted On: 09/19/2025 11:48:08 AM
Last year I submitted Leronlimab's name to the Recover TLC project who were looking for treatments for Long Covid. A few days ago I had an email exchange with the Project which I've copied below. The earliest email is at the bottom and the last at the top.
I have only minimal understanding of medicine, most of which I've learned on this website. If any of the many learned posters here have suggestions of what else I should send the Project please let me know and I'll pass it on. Ganesha
Recover TLC Submissions
From:recover-tlc-submissions@nih.gov
To: Ganesha
Tue, Sep 16 at 2:02 PM
Thanks, Ganesha!
From: Ganesha
Sent: Monday, September 15, 2025 4:33 PM
To: Recover TLC Submissions <recover-tlc-submissions@nih.gov>
Subject: [EXTERNAL] Re: RECOVER-TLC Therapeutics Portal: Leronlimab - Request for More Information
Hello: I'm not sure if this is what you're requesting but this is the url for the Results table from ClinicalTrials.gov for Long Covid trial NCT04678830:
https://www.clinicaltrials.gov/study/NCT04678830?tab=results
On Monday, September 15, 2025 at 12:44:48 PM PDT, Recover TLC Submissions <recover-tlc-submissions@nih.gov> wrote:
Hello,
We thank you for taking the time to submit leronlimab to the RECOVER-TLC online therapeutics portal.
Leronlimab underwent formal review, and reviewers would like to assess primary and secondary endpoint data from the Long COVID trial (NCT04678830). The published results we found from the trial were related to CCR5 expression (PMCID: PMC9383814 and PMCID: PMC8640501).
If you're aware of endpoint data available for assessment, we would appreciate the chance to review it.
Thank you!
I have only minimal understanding of medicine, most of which I've learned on this website. If any of the many learned posters here have suggestions of what else I should send the Project please let me know and I'll pass it on. Ganesha
Recover TLC Submissions
From:recover-tlc-submissions@nih.gov
To: Ganesha
Tue, Sep 16 at 2:02 PM
Thanks, Ganesha!
From: Ganesha
Sent: Monday, September 15, 2025 4:33 PM
To: Recover TLC Submissions <recover-tlc-submissions@nih.gov>
Subject: [EXTERNAL] Re: RECOVER-TLC Therapeutics Portal: Leronlimab - Request for More Information
Hello: I'm not sure if this is what you're requesting but this is the url for the Results table from ClinicalTrials.gov for Long Covid trial NCT04678830:
https://www.clinicaltrials.gov/study/NCT04678830?tab=results
On Monday, September 15, 2025 at 12:44:48 PM PDT, Recover TLC Submissions <recover-tlc-submissions@nih.gov> wrote:
Hello,
We thank you for taking the time to submit leronlimab to the RECOVER-TLC online therapeutics portal.
Leronlimab underwent formal review, and reviewers would like to assess primary and secondary endpoint data from the Long COVID trial (NCT04678830). The published results we found from the trial were related to CCR5 expression (PMCID: PMC9383814 and PMCID: PMC8640501).
If you're aware of endpoint data available for assessment, we would appreciate the chance to review it.
Thank you!
(19)
(0)